Sequence 1 (CDK4 , CDK16 , FIP1L1 , HCK , MAPK1 , MAPK9 ( Homo sapiens ))

Sequence CDK4 , CDK16 , FIP1L1 , HCK , MAPK1 , MAPK9 ( Homo sapiens )
Target	CDK4 , CDK16 , FIP1L1 , HCK , MAPK1 , MAPK9 ( Homo sapiens )
Description	ENSG00000135446 12:57747727-57756013:-1 Cyclin-dependent kinase 4 ; ENSG00000102225 X:47217860-47229997:1 Cyclin-dependent kinase 16 ; ENSG00000145216 4:53377643-53460861:1 Factor interacting with PAPOLA and CPSF1 ; ENSG00000101336 20:32052188-32101856:1 HCK proto-oncogene, Src family tyrosine kinase ; ENSG00000100030 22:21754500-21867680:-1 Mitogen-activated protein kinase 1 ; ENSG00000050748 5:180233143-180292099:-1 Mitogen-activated protein kinase 9
Design	Gapmer
Chemistry	+G*+G*+C*C*A*G*G*C*C*A*A*A*G*+T*+C*+A
Sequence	GGCCAGGCCAAAGTCA
Application	Gene silencing , multitargeting
Name	CDK4 , CDK16 , FIP1L1 , HCK , MAPK1 , MAPK9 ( Homo sapiens )

References

Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes. Varela MA. BMC Genomics. 2015 Jul 18;16(1):530.

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience. Hache M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S, Bishop KM. J Child Neurol. 2016 Jun;31(7):899-906. PubMed:26823478

Comments

Not experimentally validated

Background